Design and development of mucosal vaccine vectors in commensal bacteria expressing SARS-CoV-2 antigens - a potential prophylactic method | Pandemic PACT Tracker

Key facts

Disease
COVID-19
Start & end year
N/A
Known Financial Commitments (USD)
$180,000
Funder
National Research Foundation of Korea (NRF), Swedish Research Council
Principal Investigator
Lars Engstrand
Research Location
Sweden
Lead Research Institution
Karolinska Institutet
Research Priority Alignment
N/A

Research Category
Vaccines research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
Innovation
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

Medical biotechnology (specializing in cell biology (incl. Stem cell biology), molecular biology, microbiology, biochemistry or biopharmacy)

2 Publications linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

Oral Immunisation With Non-GMO Surface Displayed SARS-CoV-2 Spike Epitopes on Bacteria-Like Particles Provokes Robust Humoral and Cellular Immune Responses, and Modulated the Gut Microbiome in Mice.

Hacking Commensal Bacteria to Consolidate the Adaptive Mucosal Immune Response in the Gut-Lung Axis: Future Possibilities for SARS-CoV-2 Protection.